Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources


September 29, 2025

Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults

European Respiratory Society (ERS) 2025 Congress – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025

The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models

European Academy of Dermatology & Venereology (EADV) 2025
Atopic Dermatitis (AD) Asthma
Read More
September 17, 2025

KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects

European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
Healthy Volunteers
Read More
May 19, 2025

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically

American Thoracic Society (ATS) 2025
Read More
May 17, 2025

Revolutionizing Immunology: Oral Medicines with Biologics-like Activity

American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
April 17, 2025

Cell Chemical Biology: CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers

Kwiatkowski, et al.
Read More
March 8, 2025

Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults

Agarwal, et al.
Read More
December 9, 2024

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

American Society of Hematology (ASH) 2024
Other
Read More
December 9, 2024

Molecular Cancer Therapeutics: KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors

Chutake, et al.
Read More
October 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More